Tevapharm
Bookmark
ShareCopied to clipboardTevapharm is a company. It is a public company in Tel Aviv, Israel. It was founded in 1901 and its current CEO is Richard D. Francis. It is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Tel Aviv
- country: Israel
- employees: 33,892 people
- revenues: 16.5B $
- company type: public
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1901
- CEO: Richard D. Francis
- CEO approval: 88 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Tevapharm:
Dataset of stocks from Tevapharm:
Tevapharm is one of the companies in Israel, companies in Pharmaceuticals, companies in Health Care, companies in Tel Aviv and 3,456,808 companies in our database.
Talking Points
- Just a moment...
- Official Teva US Twitter feed. We don't just make medicines, we make a difference in people's lives. By Corp Comms. Guidelines: https://t.co/sOC1rpJ9tr
- Committed to improving health for people around the world. | Teva Pharmaceuticals has been developing and producing medicines to help improve people's lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3500 products in nearly every therapeutic area.
- Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.